New coronavirus disease (COVID-19) and cardiovascular disease

Барбараш, О. Л.; Каретникова, В. Н.; Кашталап, В. В.; Зверева, Т. Н.; Кочергина, А. М.

doi:10.17802/2306-1278-2020-9-2-17-28

Cited by 28 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В условиях пандемии COVID-19 для больных ИБС с ОКС сохраняется необходимость проведения РМ, что требует изменения алгоритма работы экстренных служб по оказанию помощи и перестройки маршрутизации данных пациентов [6].…”

Section: Discussionunclassified

Myocardial revascularization in patients with acute coronary syndrome in the context of COVID-19 pandemic: a single-center prospective cohort study

et al. 2021

View full text Add to dashboard Cite

Aim. To assess the outcomes of myocardial revascularization (MR) and identify risk factors for early postoperative complications in patients with coronary artery disease (CAD) with acute coronary syndrome (ACS) in the context of coronavirus disease 2019 (COVID-19) pandemic.Material and methods. The study included 769 patients aged 67,0±4,4 years with CAD with ACS in the period from April to October 2020. In an expedited manner, percutaneous transluminal coronary angioplasty (n=699) and on pump coronary artery bypass grafting (CABG) (n=70) were performed. All patients underwent a COVID-19 rapid tests. After MR, the following outcomes were recorded: adverse cardiovascular events and other complications; various surgical interventions; bilateral COVID-19 pneumonia; death. The follow-up period lasted 30 days.Results. During the hospitalization, COVID-19 was detected in 5,3% of patients (n=41). Among them, bilateral multisegmental pneumonia developed in 48,8%. Among infected patients, COVID-19-related mortality in the early postoperative period was 9,8%. The all-cause mortality rate was 0,7%. On pump CABG significantly increases the risk of developing COVID-19 pneumonia (odds ratio (OR), 23,2; 95% confidence interval (CI) 14,2-35,4; p<0,001). After MR, COVID-19 pneumonia was associated with respiratory (OR, 7,6; 95% CI, 4,3-11,5; p=0,001) and heart failure (OR, 4,2; 95% CI, 2,9-8,6; p=0,001), atrial fibrillation (OR, 8,3; 95% CI, 4,1-13,9; p=0,001), as well as with all-cause mortality (OR, 10,3; 95% CI, 5,2-16,7; p=0,005). Recurrent transmural myocardial infarction in patients with CAD was associated with heart failure after MR (OR, 7,1; 95% CI, 2,4-12,6; p=0,012).Conclusion. Conducting on pump CABG in patients with CAD with ACS is the leading trigger for developing COVID-19 pneumonia, which, during hospitalization after MR, was associated not only with respiratory complications, but also with impaired heart function, which significantly increases the death risk in this category of patients.

show abstract

Section: Discussionunclassified

Myocardial revascularization in patients with acute coronary syndrome in the context of COVID-19 pandemic: a single-center prospective cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Действительно, мембранные рецепторы ангиотензин-превращающего фермента 2-го типа (АПФ2), помимо легких, выявлены на поверхности клеток эндотелия, гладкомышечных клеток, кардиомиоцитов и пр. [16,17]. Недавно российские авторы опубликовали описание клинического случая коронавирусного поражения миокарда у пожилой пациентки с артериальной гипертонией [18].…”

Section: Discussionunclassified

COVID-19 in solid organ transplant recipients: initial report from national multicenter observational study «ROKKOR-recipient»

Gautier

Шевченко

Цирульникова

et al. 2020

RJTAO

View full text Add to dashboard Cite

We herein present our initial report from «ROKKOR-recipient», a national multicenter observational study. The prevalence, risk factors, clinical manifestations and outcomes of the novel coronavirus disease 2019 (COVID-19) in solid organ transplant recipients receiving immunosuppressive therapy were investigated. The study enrolled 251 COVID-19 patients (220 kidney recipients, 7 liver recipients, 1 liver-kidney recipient, and 23 heart recipients). The subjects came from 20 regions in Russia. The symptoms, clinical presentation, imaging and lab test results, therapy and outcomes of COVID-19 were described. It was established that solid organ transplant recipients with COVID-19 have a higher risk of developing adverse events. Predictors of adverse events include associated cardiovascular diseases, pulmonary diseases, diabetes, and kidney failure. Symptoms of the disease include dyspnea, rash and catarrhal signs, as well as initial low blood oxygen saturation (SpO2 <92%), leukocytosis (white blood cell count >10 × 109/L), elevated creatinine levels (>130 μmol/L) and a marked decrease in glomerular filtration rate, requiring hemodialysis. Performing organ transplant surgery in COVID-19 does not increase the risk of adverse events but could save the lives of waitlisted terminally ill patients.

show abstract

“…The results of studies by researches both in Russia and abroad indicate that damage to the cardiovascular system (CVS) is observed in 20-30% of patients with COVID-19 [1,2,3]. The combination of CVD and COVID-19 produces additional difficulties in diagnosing, determining priority tactics and choosing therapy.…”

Section: Relevance Of the Problemmentioning

confidence: 99%

Features of the course of cardiovascular diseases against the background of COVID-19

Betuganova¹,

Notov²,

Ahkubekova³

et al. 2022

View full text Add to dashboard Cite

show abstract

New coronavirus disease (COVID-19) and cardiovascular disease

Cited by 28 publications

References 32 publications

Myocardial revascularization in patients with acute coronary syndrome in the context of COVID-19 pandemic: a single-center prospective cohort study

Myocardial revascularization in patients with acute coronary syndrome in the context of COVID-19 pandemic: a single-center prospective cohort study

COVID-19 in solid organ transplant recipients: initial report from national multicenter observational study «ROKKOR-recipient»

Features of the course of cardiovascular diseases against the background of COVID-19

Contact Info

Product

Resources

About